Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q1 2019 · 10-Q
Revenue$43.48M$43.48M−22.6% vs Q1 2018 Net Income$666.34M$666.34M+1,371.6% vs Q1 2018 EPS Diluted$31.32$31.32+1,611.5% vs Q1 2018 Operating Income$826,543,000+2,131.4% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Margins · derivedOperating margin1900.8%+1834.8 pt vs Q1 2018
Net margin1532.4%+1451.7 pt vs Q1 2018
ended Mar 31, 2019 · filed May 9, 2019 · 39 d after period end